Lambda Therapeutic Research stands at the forefront of the global Clinical Research Organization (CRO) landscape, with its headquarters in Ahmedabad, India, and a presence extending across Mehsana (India), Las Vegas (USA), Pittsburgh (USA), Toronto (Canada), London (UK), Barcelona (Spain) and Warsaw (Poland).

Our unwavering mission revolves around providing comprehensive end-to-end clinical research services to the global innovator, biotech, and generic pharmaceutical industries. Lambda consistently sets new standards in the Clinical Research sector, achieving milestones through both organic growth and strategic acquisitions. In 2019, we strategically expanded our North American presence by acquiring Novum Pharmaceutical Research Services, a distinguished 50-year-old CRO. This strategic move, following the integration of Biovail’s R&D facilities in Canada in 2010, marked Lambda’s second significant acquisition in North America. Operating under the unified brand of Novum Pharmaceutical Research Services in North America, Lambda reinforces its position as a key player in the global CRO market.

Our commitment to excellence is evident through the substantial investment in a team of over 1200 professionals and cutting-edge digital platforms. Prioritizing secure IT infrastructure and automation, Lambda ensures timely project delivery, adhering to global regulatory standards. Our outstanding regulatory track record is underscored by over 60 successful international inspections and audits conducted by esteemed authorities, including the USFDA, EMEA, MHRA, EU member states, and other global bodies over the past five years.

Lambda has been recognized for its expertise and commitment to quality, earning several prestigious industry awards. We were honored as the ‘Best Indian CRO’ by Frost & Sullivan (USA) and recognized as a ‘Great Indian Workplace’ by UBS Transformance. More recently, we received the ‘Regulatory Excellence‘ Award at the CPhI Awards 2023 and were awarded the ‘Industry Partner of the Year‘ Award at the Global Generics & Biosimilar Awards 2023. Industry Outlook has also highlighted Lambda among the ‘Top 10 CROs‘ in 2022 and ‘Top 10 Contract Research Organizations‘ in 2023. These accolades reflect our strong focus on regulatory compliance, industry leadership, and meaningful collaborations in the biotech, pharmaceutical, and clinical research sectors.